Bischlorethylnitrosourea en es it fr

Bischlorethylnitrosourea Brand names, Bischlorethylnitrosourea Analogs

Bischlorethylnitrosourea Brand Names Mixture

  • No information avaliable

Bischlorethylnitrosourea Chemical_Formula


Bischlorethylnitrosourea RX_link

Bischlorethylnitrosourea fda sheet

Bischlorethylnitrosourea msds (material safety sheet)

Bischlorethylnitrosourea MSDS

Bischlorethylnitrosourea Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Bischlorethylnitrosourea Molecular Weight

214.049 g/mol

Bischlorethylnitrosourea Melting Point

31 oC

Bischlorethylnitrosourea H2O Solubility

< 0.1 g/100 mL at 18 °C

Bischlorethylnitrosourea State


Bischlorethylnitrosourea LogP


Bischlorethylnitrosourea Dosage Forms

Powder for solution; Wafer

Bischlorethylnitrosourea Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Bischlorethylnitrosourea Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Bischlorethylnitrosourea Absorption

5 to 28% bioavailability

Bischlorethylnitrosourea side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Bischlorethylnitrosourea Patient Information

No information avaliable

Bischlorethylnitrosourea Organisms Affected

Humans and other mammals